Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-228 and metformin in advanced cancers
NCT03017833Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sapanisertib in malignant solid neoplasm, Recurrent malignant neoplasm and Neoplasm, sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2018; status: completed.
02
Drugs
sapanisertib
03
Conditions
malignant solid neoplasmRecurrent malignant neoplasmNeoplasm
Beyond the preview
Go deeper on NCT03017833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03017833.